Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration
Hamilton Se‐Hwee Oh, Joshua D. Downer, Connor D. Dietz, Claire Yballa, Edoardo M. Marcora, Argentina Lario‐Lago, Hilary W. Heuer, Leah K. Forsberg, Jennifer Hsiao‐Nakamoto, Chi‐Lu Chiu, Paul Auger, Casey A. Powers, Gilbert Di Paolo, Fen Huang, Brian Stephen Appleby, , Scott J. Russo
The paper identifies the CSF YWHAG:NPTX2 ratio as a biomarker for predicting clinical severity and phenoconversion in FTLD, showing strong correlation with disease progression and improved trial design potential.
bioRxiv · Aug 31, 2026 · PreprintNeuroscience